Traversa Therapeutics Inc.

Two new biopharma companies pursuing very different business models have raised nearly $50 million, with San Francisco venture firm venBio leading both Series A rounds. VenBio launched formally in 201

Despite a miserable economy, new company formation continues apace. In biotech, recapitalizations and structured deals featured prominently; in diagnostics, interest remains strong even if rounds in 2

Novel treatments for this invasive brain cancer offer patients hope--and their developers potential profits. As adverse side effects or potential safety signals trigger increasing regulatory scrutiny

Hoping to deliver on RNAi 505 Coast Boulevard South La Jolla, CA 92037 Phone: (858) 454-8400 Fax: (858) 454-4750 Web Site: www.traversathera.com Contact: Hans Petersen, President & CEO Industry Segm